Sector
PharmaceuticalsOpen
₹220.8Prev. Close
₹221Turnover(Lac.)
₹195.35Day's High
₹223.85Day's Low
₹217.352 Week's High
₹472.852 Week's Low
₹196.1Book Value
₹3.84Face Value
₹1Mkt Cap (₹ Cr.)
7,257.28P/E
0EPS
0Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 32.45 | 32.45 | 261.45 | 26.21 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 92.4 | 480.32 | -230.22 | -194.46 |
Net Worth | 124.85 | 512.77 | 31.23 | -168.25 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 252.95 | 76.81 | 78.25 | 181.02 |
yoy growth (%) | 229.3 | -1.84 | -56.76 | 12.24 |
Raw materials | -18.17 | -23.92 | -26.8 | -25.16 |
As % of sales | 7.18 | 31.14 | 34.25 | 13.89 |
Employee costs | -91.58 | -93.08 | -100.92 | -84.3 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | -151.13 | -312.4 | -245.97 | -119.03 |
Depreciation | -10.92 | -9.48 | -8.18 | -8.23 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | 59.11 | -68.31 | -89.36 | 46.78 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 229.3 | -1.84 | -56.76 | 12.24 |
Op profit growth | -56.46 | 27.78 | 97.72 | 94.16 |
EBIT growth | -54.64 | 25.98 | 109.73 | 72.79 |
Net profit growth | -51.62 | 58.58 | 65.49 | 70.07 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 |
---|---|---|
Gross Sales | 75.55 | 238.78 |
Excise Duty | 0 | 0 |
Net Sales | 75.55 | 238.78 |
Other Operating Income | 0 | 0 |
Other Income | 29.47 | 10.88 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Director
T Rajamannar
Director
Sudhir V Valia
Independent Director
Bhavna Doshi
Independent Director
Ferzaan Engineer
Independent Director
Robert Spiegel
Chairman (Non-Executive)
Dilip S Shanghvi
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Sun Pharma Advanced Research Company Ltd
Summary
Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical stage bio-pharmaceutical company engaged in creating new drugs and delivery systems. The Company works on innovation and new product development for global markets. They undertake projects in research and technology for new chemical entities (NCEs) or new molecules, and novel drug delivery systems (NDDS). Sun Pharmaceutical Advanced Research Company Ltd was incorporated on March 1, 2006 as an innovative and development company. They commenced operations on March 22, 2006. As per Scheme of Arrangement, all assets and liabilities of the Innovative Research & Development business including Novel Drug Delivery System (NDDS) division of Sun Pharmaceuticals Industries Research & Development undertaking stands transferred and vested in the Company with effect from Appointed date on February 28, 2007. The demerger became effective on March 28, 2007. On Scheme being effective, the Company ceased to be subsidiary of Sun Pharmaceutical Industries Ltd., and the demerged Company.During the year 2009-10, the Department of Scientific and Industrial Research (DSIR), Government of India sanctioned a 15 year unsecured soft loan under their Drug and Pharmaceutical Research Programme for a project of the Company.During 2011, the Company announced USFDA approval for DOCEFREZ (docetaxel) for Injection. During 2014, the Company announced Govt. of India approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN).On 1 Decembe
Read More
The Sun Pharma Advanced Research Company Ltd shares price on N/A is Rs.₹224.8 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sun Pharma Advanced Research Company Ltd is ₹7295.25 Cr. as of 22 Jul ‘24
The PE and PB ratios of Sun Pharma Advanced Research Company Ltd is 0 and 57.38 as of 22 Jul ‘24
The 52-week high/low is the highest and lowest price at which a Sun Pharma Advanced Research Company Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Sun Pharma Advanced Research Company Ltd is ₹196.45 and ₹474 as of 22 Jul ‘24
Sun Pharma Advanced Research Company Ltd's CAGR for 5 Years at 7.88%, 3 Years at -3.41%, 1 Year at 0.27%, 6 Month at -41.10%, 3 Month at -33.84% and 1 Month at -5.11%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.